Oligodendrocytes, which differentiate from oligodendrocyte precursor cells (OPCs), ensheath axons with myelin, play an essential role in rapid conduction of action potentials and metabolically support neurons. Elucidation of the mechanisms underlying the proliferation, migration, differentiation, and survival of OPCs is considered indispensable for determining the causes of central nervous system diseases. However, the relationship between these functions of OPCs and their intracellular Ca 2+ signaling has not been fully elucidated. Here, we investigated the function of transient receptor potential vanilloid 4 (TRPV4), a Ca 2+ -permeable channel that responds to hypo-osmolarity, mild temperature, mechanical stimulation, and endogenous arachidonic acid metabolites, in OPCs. Trpv4 mRNA was detected in OPCs in vivo and in primary cultured rat OPCs. In Ca 2+ imaging experiments, treatment with the selective TRPV4 agonist GSK1016790A induced sustained elevation of the intracellular Ca 2+ concentration in OPCs in a concentrationdependent manner, which was almost completely suppressed by co-treatment with the selective TRPV4 antagonist HC067047. Stimulation of TRPV4 by GSK1016790A augmented OPC proliferation, which was abolished by co-treatment with HC067047, the intracellular Ca 2+ chelator BAPTA-AM, and the protein kinase C inhibitor bisindolylmaleimide II. By contrast, GSK1016790A did not significantly affect the migration or differentiation of OPCs. Taken together, these results suggest that TRPV4 is functionally expressed in OPCs and increases the proliferation of these cells without affecting their ability to differentiate into oligodendrocytes.
Introduction
Oligodendrocytes are a type of glial cell and ensheath axons with myelin. Consequently, they not only allow rapid conduction of electrical impulses [45] but also metabolically support neurons [23] . Oligodendrocyte precursor cells (OPCs) proliferate, migrate, and differentiate into oligodendrocytes.
Demyelination and white matter injury are observed in various central nervous system (CNS) diseases, such as multiple sclerosis [15] , Alzheimer's disease [14] , and psychiatric diseases [31] . Therefore, appropriate regulation of the survival, proliferation, migration, and differentiation of OPCs can effectively improve the pathology of these diseases. Proliferation of OPCs is the first step in remyelination after CNS injury. OPCs die in multiple sclerosis, leading to poor remyelination [9] . Recent reports indicate that OPCs not only differentiate into myelinating oligodendrocytes but also secrete brainderived neurotrophic factor (BDNF) and protect neurons against apoptosis [5, 43] . Therefore, increasing the number of OPCs is considered a major strategy to promote remyelination and functional recovery after CNS damage [11, 22] .
Although the intracellular signaling that regulates OPC functions remains to be clarified, many studies have investigated molecules that influence these behaviors, such as sonic hedgehog, Wnt proteins, N-methyl-D-aspartate (NMDA), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), neuregulin, and BDNF [3, 13, 24, 25, 32] . Several studies reported that AMPA receptors [10] , P2X purine receptors [16] , and voltage-dependent Ca 2+ channels [6] elevate the intracellular Ca 2+ concentration ([Ca 2+ ] i ) in OPCs. Stimulation of these receptors/channels modulates the proliferation [6] , morphology [10] , differentiation, and myelination [6] of OPCs. Moreover, PDGF and FGF induce Ca 2+ responses [33] . However, the detailed Ca 2+ signaling mechanisms have not been fully understood.
Transient receptor potential (TRP) channels are Ca
2+
-permeable, non-selective, cation channels with multiple functions. Twenty-eight mammalian TRP genes comprising six families (TRPC, TRPM, TRPV, TRPA, TRPP, and TRPML) have been identified [46] . Some TRP channels have been detected in oligodendrocyte lineage cells. For example, TRPC1 activation is involved in store-operated Ca 2+ influx in OPCs and increases their proliferation [34] . At the onset of myelination, TRPM3 is expressed in oligodendrocytes and its activation induces Ca 2+ responses in these cells [18] . TRPA1 is functionally expressed in mature oligodendrocytes, and an increase in the [Ca 2+ ] i via this proton-gated channel contributes to myelin damage [17] . However, the relationship between the other TRP channels and the functions of oligodendrocyte lineage cells is poorly understood.
This study focused on transient receptor potential vanilloid 4 (TRPV4), which can sense a variety of environmental stimuli such as temperature, osmolarity, mechanical stretch, and arachidonic acid metabolites. We report that TRPV4 is expressed in OPCs in vivo and in primary cultured rat OPCs. Additionally, stimulation of TRPV4 by its selective agonist GSK1016790A increased OPC proliferation via Ca 2+ influx and the protein kinase C (PKC) pathway. Our results indicate that TRPV4 increases the proliferation of OPCs without affecting their ability to differentiate into mature oligodendrocytes.
Materials and methods

Fluorescence in situ hybridization and immunohistochemistry
Immunohistochemistry and fluorescence in situ hybridization (FISH) were performed as previously described [38, 39] . The Trpv4, PDGFRa, plp, and gfap cRNA riboprobes were described previously [26, 27, 38] . Biotin-and digoxigeninlabeled cRNA riboprobes were prepared as previously described [39] . Sagittal sections of 8-week-old mouse brains were hybridized with a mixture of biotin-and digoxigeninlabeled cRNA probes in hybridization buffer. Following washing, digoxigenin and biotin were detected via a twostep method. Biotin was first detected with peroxidaseconjugated streptavidin (PerkinElmer; 1:100 dilution, 1 h) and a fluorescein isothiocyanate-tyramide signal amplification (TSA) Plus Kit (PerkinElmer). Then, after incubation with 1.0% H 2 O 2 for 30 min to inactivate residual peroxidase, digoxigenin was detected by labeling with a peroxidaseconjugated anti-digoxigenin antibody (Roche Diagnostics; 1:500 dilution, 1 h) and an indocarbocyanine-TSA Plus Kit (PerkinElmer). An anti-Iba1 antibody (1:500 dilution, Wako) and Alexa Flour 564-conjugated goat anti-rabbit IgG (1:2000 dilution) were used to detect Iba1 after Trpv4 FISH. Sections were examined using a fluorescence microscope (BX53, Olympus) equipped with a cooled CCD camera (DP80, Olympus).
Primary culture of OPCs
All experiments were conducted in accordance with the ethical guidelines set down by the Kyoto University Animal Research Committee. Primary OPC cultures were prepared from cerebral cortices of 0-2-day-old Wistar/ST rats (Japan SLC). After isolation of cerebral cortices, cells were incubated with trypsin (2.5 mg/mL; Nacalai Tesque) and DNase I (25 μg/mL; D5025, Sigma-Aldrich) for 15 min at 37°C. Dissociated cells were plated onto poly-L-ornithine-coated 75-cm 2 flasks in Dulbecco's modified Eagle's medium (D5796, Sigma-Aldrich) containing 10% heat-inactivated fetal bovine serum and 1% penicillin/streptomycin mixed solution (Nacalai Tesque) and maintained at 37°C in a humidified atmosphere containing 5% CO 2 . After 10-15 days, OPCs were purified from the mixed glial culture via a two-step procedure. First, microglia were removed by shaking at 120-130 rpm for 1 h using an orbital shaker. After removing the supernatant and adding fresh culture medium, OPCs on a monolayer of astrocytes were detached by shaking at 230-250 rpm for 16-18 h. To remove astrocytes, the supernatant was cultured on non-coated 10 cm dishes for 1 h at 37°C in 5% CO 2 . The final cell suspension was replated onto poly-L-ornithine-coated 10 mm glass coverslips, 35 mm dishes, or 48 well plates and maintained in Neurobasal medium (Life Technologies) supplemented with 1× B27 (Life Technologies), glutamine (2 mM), 1% penicillin/streptomycin mixed solution, PDGF-AA (10 ng/mL; PeproTech), and basic FGF (10 ng/mL; PeproTech), which was used as proliferation medium. Cells were used for experiments at least 1 day after replating. To analyze OPC differentiation, 2 days after replating, proliferation medium was changed to Neurobasal medium supplemented with 1× B27, glutamine (2 mM), 1% penicillin/streptomycin mixed solution, triiodo-L-thyronine (T3; 30 ng/mL; Sigma-Aldrich), and ciliary neurotrophic factor (CNTF; 10 ng/mL; PeproTech), which was used as differentiation medium.
Immunocytochemistry
OPCs were maintained on 10-mm glass coverslips for 2 days. To analyze differentiation, cells were maintained for an additional 5 days in differentiation medium. Following fixation in 4% paraformaldehyde, cells were permeabilized in phosphatebuffered saline (PBS) containing 3% bovine serum albumin and 0.1% Triton X-100 for 30 min. To detect platelet-derived growth factor receptor α (PDGFRα) and myelin basic protein (MBP), cells were incubated with a rabbit polyclonal anti-PDGFRα antibody (1:1000; Santa Cruz) and a rat anti-MBP antibody (1:375; Millipore) for 3 h at room temperature, and then with Alexa Fluor 594-labeled donkey anti-rabbit IgG (1:500; Invitrogen) and Alexa Fluor 488-labeled donkey anti-rat IgG (1:500; Invitrogen) overnight at 4°C. After staining nuclei with DAPI Fluoromount-G (Southern Biotechnology Associates), fluorescence images were acquired using a FluoView FV10i confocal microscope (Olympus).
Reverse transcription-PCR
Total RNAwas extracted from OPCs cultured in a 35-mm dish using a Nucleo Spin RNA kit (TaKaRa Bio). First-strand cDNA was prepared from total RNA using a ReverTra Ace qPCR RT Kit (Toyobo). Rat Trpv4 cDNA was amplified by PCR using Blend Taq (Toyobo) and the following primer pair: 5′-GGTTGTGTCTGCGGCGCTCT-3′ and 5′-GTGG TGGCCCACTGCAGCTT-3′. The PCR conditions were as follows: 94°C for 2 min, followed by 30 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 1 min. Amplified PCR products were electrophoresed in an agarose gel, stained with 0.1 μg/mL ethidium bromide, and visualized under ultraviolet light. Images were captured with Quantity One software (BioRad).
Western blotting
Western blotting was performed as described previously [42] , with slight modification. After 2 days in enriched culture, cells were lysed in RIPA buffer (Nacalai Tesque). Proteins were diluted in NuPAGE® 4× LDS sample buffer (Life Technologies), loaded onto a 10% SDS-polyacrylamide gel, and blotted onto Immobilon-P PVDF transfer membranes (Millipore). After a blocking step using Blocking One (Nacalai tesque), the membranes were incubated overnight at 4°C with anti-TRPV4 antibody (ab39260, Abcam), diluted 1:250 in Tris-buffered saline containing 0.1% Tween-20 and 10% Blocking One. After washing, membranes were incubated with peroxidase-conjugated donkey anti-rabbit IgG (1:5000 dilution; GE Healthcare) for 1 h at RT. Specific bands were detected by Immobilon Western Chemiluminescent HRP substrate (Millipore) and visualized using the ChemiImager 4400 imaging system (Alpha Innotech).
Fluorometric Ca 2+ imaging
Ca 2+ imaging was conducted as previously reported [42] with slight modification. OPCs on coverslips were loaded for 30-40 min with 5 μM fura-2 acetoxymethyl ester (Fura-2 AM; Dojindo) prepared in Krebs-Ringer buffer (140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM glucose, and 10 mM HEPES, adjusted to pH 7.4) containing 0.005% Cremophor EL (Sigma-Aldrich). Fluorescence images were captured at room temperature every 2 s with the AQUACOSMOS/ORCA-AG imaging system (Hamamatsu Photonics) using alternating excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm. The ratio of the fluorescence intensity obtained with excitation/ emission wavelengths of 340 nm/510 nm (F340) to that obtained with excitation/emission wavelengths of 380 nm/ 510 nm (F380), so-called F340/F380, was calculated to quantify the [Ca 2+ ] i .
Whole-cell patch-clamp recording
Whole-cell currents were recorded at room temperature with a pipette made from a 1.5-mm outer-diameter glass capillary with a filament (Narishige) and pulled using a P-87 micropipette puller (Sutter) as previously described [29] with slight modification. Access resistance ranged from 2 to 5 MΩ when the pipette was filled with the intracellular solution described below. The bath solution contained 150 mM NaCl, 1 mM MgCl 2 , 1.5 mM CaCl 2 , 10 mM HEPES, and 10 mM Dglucose (adjusted to pH 7.4 with NaOH). The pipette solution contained 150 mM CsCl, 10 mM BAPTA 1 mM MgCl 2 , and 10 mM HEPES (adjusted to pH 7.2 with CsOH). Currentvoltage relationships were measured using voltage ramps (− 100 to + 100 mV over 200 ms, 0.2 Hz). The holding potential was set to 0 mV. Access resistance was compensated by 70%. Patch-clamp recordings were performed using an EPC-10 patch-clamp amplifier (HEKA Instruments) and PATCHMASTER software (HEKA). Data were filtered at 2.9 kHz for analysis.
Scratch-wound assay
When OPCs in 35-mm dishes were 70-80% confluent, a wound was created using a cell scraper (BM Bio). Cultures were washed twice with PBS, medium containing GSK1016790A or vehicle (dimethyl sulfoxide) was added, and cells were allowed to migrate for 6-48 h. Phase contrast images were acquired using a DIAPHOT 300 inverted phase contrast microscope (Nikon) and a DS-U1 DIGITAL SIGHT camera system (Nikon). The number of cells that migrated into the scratched area was counted.
MTT assay
Cell proliferation/viability was assessed by the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide) assay according to the manufacturer's protocol (Nacalai Tesque). Twenty-four to 72 h after the drug treatment, cells were treated with MTT (0.025 mg/mL) for 3 h, crystals were solubilized in dimethyl sulfoxide, and absorbance at 570 nm was measured. Cell viability was expressed as a ratio in comparison with non-treated control cells.
Incorporation of bromodeoxyuridine and fluorescence staining
Two days after replating onto 10-mm glass coverslips, OPCs were treated with drugs for 24 h. Thereafter, OPCs were treated with bromodeoxyuridine (BrdU; 1 μM; Sigma-Aldrich) for 3 h, fixed in 4% paraformaldehyde, and soaked in 1 N HCl for 20 min at 37°C to denature nuclear DNA. Then, cells were incubated with a mouse monoclonal anti-BrdU antibody (1:500; Roche) for 3 h at room temperature followed by Alexa Fluor 488-labeled goat anti-mouse IgG (1:500; Invitrogen) overnight at 4°C. After staining nuclei with DAPI Fluoromount-G, fluorescence images were acquired using a FluoView FV10i confocal microscope (Olympus). The percentage of BrdU + cells was estimated based on the total number of cells.
Quantitative RT-PCR
After reverse transcription of total mRNA into cDNA using a ReverTra Ace qPCR RT Kit, real-time quantitative PCR was performed using the StepOne Real-Time PCR System (Life Technologies) and THUNDERBIRD SYBR qPCR Mix (Toyobo). The primer sets were as follows: 5′-CGGT CCAAGAATTTCACCTC-3′ and 5′-ACCGCGGTTCTATT TTGTTG-3′ for rat 18S ribosomal RNA (rRNA), 5′-GATA GCTTCATGAGCCGACACCCA-3′ and 5 ′-CATTGGCA CGTACTGTGTGGTGTCA-3′ for rat Pdgfrα, and 5′-CTCT GGCAAGGACTCACACA-3′ and 5′-TGTCTCTTCCTCCC CAGCTA-3′ for rat Mbp. The PCR conditions were as follows: 95°C for 10 min, followed by 45 cycles of 95°C for 15 s and 60°C for 60 s. Expression of each gene was normalized against that of 18S rRNA, which was measured in parallel in each sample.
Statistical analysis
All data were expressed as means ± SEM. Statistical analyses were performed by Student's t test or one-way ANOVA followed by Tukey's test using GraphPad Prism 5. In all cases, P < 0.05 was considered statistically significant.
Results
OPCs express TRPV4 in vivo
We previously reported that astrocytes and microglial cells express TRPV4, in addition to neurons [21, 38, 40] , and we are keen to understand whether OPCs express TRPV4. To address this possibility, we examined Trpv4 and PDGFRα (an OPC marker) mRNA in cerebral cortex (gray matter) and corpus callosum (white matter) in P4 or adult rats by FISH (Fig. 1a) , and detected Trpv4 in most PDGFRα + OPCs (~80%, arrowheads); however, some OPCs (~20%, arrows) did not exhibit clear Trpv4 FISH signals at P4. The numbers of Trpv4/PDGFRα double-positive cells were not different between cerebral cortex and corpus callosum (Fig.  1a) . In adult, the numbers were significantly reduced in the cerebral cortex, and we observed many Trpv4/PDGFRα double-positive cells in the corpus callosum (Fig. 1a) , indicating that OPCs express TRPV4, as expected. We also performed double FISH of Trpv4 and Plp. The Plp + mature oligodendrocytes displayed clear Trpv4 signals in adult cortex and white matter (Fig. 1b) . Hence, we demonstrated that TRPV4 is expressed in OPCs and mature oligodendrocytes. Next, to examine TRPV4 expression in astrocytes, we performed double FISH of Trpv4 and gfap (an astrocyte marker). Different from the dynamic changes of the numbers of Trpv4/ PDGFRα double-positive cells between cerebral cortex and corpus callosum from P4 to adult, the numbers of Trpv4/gfap double-positive cells (arrowheads) between cerebral cortex and corpus callosum were not different from P4 to adult (Fig. 1C) . The majority of gfap + astrocytes displayed clear Trpv4 signals; however, the signals were weak in some of cells. Notably, we observed many Trpv4 − /gafp + cells, in the adult corpus callosum (Fig. 1c) , consistent with our previous reports describing TRPV4 + astrocytes formed a specific subpopulation [40, 41] . Furthermore, we confirmed the microglial TRPV4 expression by combinatorial method of FISH (Trpv4) and immunohistochemistry (Iba1, a microglial marker) at P4. Consistent with our previous report [21] , the Iba1-positive microglial cells also express the Trpv4 in both cerebral cortex and corpus callosum (Fig. 1d) . Thus, we demonstrated that TRPV4 is expressed in oligodendrocyte lineage cells in addition to the astrocytes and microglial cells in vivo.
TRPV4 is functionally expressed in cultured rat OPCs
Next, we investigated the physiological function of TRPV4 in primary cultured rat OPCs. At 2 days after replating, cells highly expressed the OPC marker PDGFRα, but not the mature oligodendrocyte marker MBP. However, at 7 days after replating, by which time cells had been cultured in differentiation medium containing T3 and CNTF for 5 days, cells highly expressed MBP and lowly expressed PDGFRα (Fig. 2a) . Next, we found that Trpv4 mRNA was detected by RT-PCR (Fig. 2b) and TRPV4 protein was detected by western blotting in OPCs cultured for 2 days in proliferation medium (Fig. 2c) ] i of OPCs in a concentration-dependent manner (Fig.  2d, e) . The increase in [Ca 2+ ] i induced by GSK1016790A (0.1 μM) was completely abolished by the selective TRPV4 antagonist HC067047 (10 μM) (Fig. 2f) . Repeated application of GSK1016790A (0.1 μM) revealed that TRPV4 antagonism by HC067047 (10 μM) was reversible (Fig. 2g) . Whole-cell patch-clamp analysis revealed that extracellular application of GSK1016790A evoked a current response (Fig. 2h) and the current-voltage curves were outwardly rectifying (Fig. 2i) , which is consistent with the results of a previous study using TRPV4 + microglia [21] . HC067047 (30 μM) inhibited the GSK1016790A-induced current (Fig. 2h, i) . These results indicate that TRPV4 is functionally expressed in cultured rat OPCs.
TRPV4 stimulation enhances the proliferation of OPCs via PKC
To investigate whether TRPV4 stimulation increases the proliferation of OPCs, we analyzed cell viability and proliferation by the MTT and BrdU incorporation assays, respectively.
Trpv4
PDGFRα Merged GSK1016790A treatment increased cell viability in a concentration-dependent manner (Fig. 3a) . The significant increase in cell viability induced by GSK1016790A (0.1 μM) was completely abolished by co-treatment with HC067047 (10 μM), whereas HC067047 alone did not significantly affect cell viability (Fig. 3b) . The mean percentage of BrdU + proliferating cells was significantly higher in the group treated with GSK1016790A (0.1 μM) than in the control group; however, this increase was completely suppressed by treatment with HC067047 (10 μM) (Fig. 3c, d ), suggesting that TRPV4 stimulation enhances OPC proliferation. We investigated the mechanism by which TRPV4 activation increases the proliferation of OPCs. To determine whether it is mediated by Ca 2+ influx through TRPV4, we used the intracellular Ca 2+ chelator BAPTA-AM. Treatment with BAPTA-AM (3 μM) significantly blocked GSK1016790A-induced OPC proliferation (Fig. 3d) . Moreover, treatment with the PKC inhibitor bisindolylmaleimide II (BIM II; 0.5 μM) also significantly blocked this increase in OPC proliferation (Fig. 3e) . These data suggest that TRPV4 stimulation promotes OPC proliferation via PKC.
TRPV4 is not involved in the migration of OPCs
To assess the other roles of TRPV4 in OPCs, we performed a scratch-wound assay using a monolayer of OPCs and examined the effect of GSK1016790A on their migration. OPCs migrated for 6-48 h; however, the number of cells in the scratched area did not significantly differ between control and GSK1016790A-treated cultures at any time point (Fig. 4a, b) . The total cell viability at 24 and 48 h after the scratch and drug treatment was significantly increased in the GSK1016790A-treated group (Fig. 4c) , indicating the involvement of TRPV4 in cell proliferation. These results indicate that activation of TRPV4 increases OPC proliferation, but not migration.
TRPV4 stimulation does not affect the differentiation of OPCs
To investigate whether TRPV4 stimulation promotes the differentiation of OPCs, we analyzed the mRNA levels of Pdgfrα and Mbp, which are markers of OPCs and mature oligodendrocytes, respectively, by quantitative PCR. In Fig. 3 TRPV4 stimulation enhances the proliferation of OPCs via PKC. a, b OPCs were treated with the TRPV4 selective agonist GSK1016790A at the indicated concentrations and with the TRPV4 selective antagonist HC067047 (10 μM) for 24 h. *P < 0.05, ***P < 0.001 vs. control; ### P < 0.001 vs. GSK1016790A (0.1 μM) alone; n = 6-8. OPC viability was evaluated by the MTT assay. c Representative confocal microscopy images of BrdU incorporation by OPCs cultured in control medium (upper) and GSK1016790A (0.1 μM)-containing medium (lower). Proliferating OPCs and total cells were identified by BrdU and DAPI staining, respectively. Scale bar, 50 μm. d, e The percentage of DAPI + cells that were BrdU + in each experimental condition. Cells were treated with drugs together with GSK1016790A (0.1 μM) for 48 h. All data are expressed as mean ± SEM. *P < 0.05 vs. control; ## P < 0.01 vs. GSK1016790A (0.1 μM) alone; n = 3 Fig. 2 TRPV4 is functionally expressed in cultured rat OPCs. a Immunostaining of PDGFRα and MBP. OPCs were cultured for 2 days in proliferation medium (day 2). To generate mature oligodendrocytes, cells were cultured for an additional 5 days in differentiation medium (day 7). Scale bar, 50 μm. b RT-PCR of Trpv4. Cells were cultured for 2 days in proliferation medium. The marker (M) shows a 100 bp DNA ladder. c Western blot image of TRPV4. OPCs were cultured for 2 days in proliferation medium. d, e Ca 2+ responses evoked by treatment with the selective TRPV4 agonist GSK1016790A at the indicated concentrations (0.01-0.1 μM). f Changes in the [Ca 2+ ] i after administration of GSK1016790A (0.1 μM) in the presence of the selective TRPV4 antagonist HC067047 (10 μM). g Changes in the [Ca 2+ ] i after perfusion of GSK1016790A (0.1 μM) with or without HC067047 (10 μM). h, i Whole-cell current recording following treatment with GSK1016790A (0.1 μM) alone or together with HC067047 (30 μM). A typical trace is shown in h, and the current-voltage relationship is shown in i. The hatched bars and white bars denote when GSK1016790A and HC067047 were applied, respectively proliferation medium, the mRNA levels of Pdgfrα and Mbp did not significantly differ between control and GSK1016790A (0.1 μM)-treated cells for 24 h, although the former was significantly downregulated and the latter was significantly upregulated in differentiation medium (Fig. 5a,  b) . These results suggest that TRPV4 stimulation does not significantly affect OPC differentiation. Moreover, in differentiation medium, the mRNA levels of Pdgfrα and Mbp did not significantly differ between control and GSK1016790A (0.1 μM)-treated cells (Fig. 5c, d ) for 72 h, whereas there were no significant differences in the cell viability (Fig. 5e) . Additionally, we evaluated the ratios of PDGFRα-and MBP-positive cells in the presence or absence of GSK1016790A by immunostaining and found that the ratios of PDGFRα-and MBP-positive cells did not significantly differ between the GSK1016790A-treated group and control group, either in proliferation medium or in differentiation medium ( Fig. 5f-k) . This confirms that TRPV4 stimulation does not significantly affect OPC differentiation and that TRPV4 increases the proliferation of OPCs by accelerating their proliferation, not by suppressing their differentiation.
Discussion
This study demonstrates that TRPV4 is expressed in OPCs in vivo and in cultured rat OPCs and that stimulation of TRPV4 by the selective agonist GSK1016790A induced Ca 2+ responses, which was almost completely suppressed by the selective TRPV4 antagonist HC067047. TRPV4 stimulation enhances the proliferation of OPCs via Ca 2+ influx and the PKC pathway, but not their migration or differentiation. These results indicate that TRPV4 increases the proliferation of OPCs, without affecting their ability to differentiate into mature oligodendrocytes.
In the proliferation assay of the present study, inhibition of TRPV4 by application of the specific TRPV4 antagonist HC067047 did not change the proliferation of OPCs. These results indicate that the functional involvement of TRPV4 in OPC proliferation is very limited in homeostatic conditions, consistent with non-histological abnormalities (normal white matter thickness) in TRPV4KO brain [38] . Meanwhile, TRPV4 activation by GSK1016790A significantly increased the proliferation of OPCs. This result suggests that TRPV4 might be activated under certain specific conditions in the brain, leading to the enhancement of proliferation. Indeed, the number of OPCs in the scratched area was higher in the GSK1016790A-treated group than in the control vehicletreated group after 48 h scratching, although the difference was not significant. This may be due to the increased proliferation of GSK1016790A-treated cells responded to the pathological events.
Which endogenous molecules open TRPV4 in OPCs in the brain? Very recently, it is reported that lipopolysaccharides, the major components of the wall of Gram-negative bacteria, directly activate the TRPV4 [2] . In demyelinated region, many inflammatory molecules (proteins, sugar chains, or lipids) were released from myelin debris or damaged axons. Therefore, some of those molecules might activate TRPV4 Cell viability was evaluated by MTT assay. OPCs were treated with vehicle or GSK1016790A (0.1 μM) for 24 or 48 h after the scratch. **P < 0.01 vs. control; n = 3. All data are expressed as mean ± SEM in OPCs and increase the proliferation of OPCs under demyelinated pathological conditions. TRPV4 is also activated by 5′, 6′-epoxyeicosatrienoic acid [44] , which is a signaling molecule formed in various cell types via metabolism of arachidonic acid. Arachidonic acid is upregulated in the brain in response to traumatic brain injury [47] . OPCs proliferate in response to CNS injury [28] , and this may be mediated by stimulation of TRPV4 via arachidonic acid metabolites during brain inflammation. Hypo-osmolarity and mechanical stretch also are activators of TRPV4 [30] . Given that cells generate traction force during division [19] and the mechanically gated ion channel Piezo 1 can respond to such force in neural stem cells [36] , TRPV4 may be open while OPCs are dividing and increase their proliferation. TRPV4 is also activated by white matter components. White matter is composed of many different components including extracellular matrix (ECM) such as laminin and collagen, and it is reported that laminin-2 induced oligodendrocytes spreading through the integrin signaling [8] . Interestingly, it is also reported that TRPV4 physically interacted with the integrin and affected mechanical shown in panels j and k, respectively. n = 3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control cells cultured in proliferation medium All data are expressed as mean ± SEM hyperalgegia [1] . Therefore, it is highly possible that the TRPV4 is significantly sensitized under endogenous ECM conditions in the white matter. Unfortunately, our physiological assay to reveal the involvement of TRPV4 was performed in vitro conditions. Hence, we might fail to mimic the intrinsic TRPV4 involvement in OPC physiological dynamics. We need specific in vivo experiments to reveal physiological impacts of the TRPV4 on OPCs as our next studies. Mild temperature (> 27-34°C), too, can activate TRPV4 [38] . Pharmacological blockade of TRPV4 by HC067047 alone did not affect the proliferation of OPCs at 37°C in this study, suggesting that body temperature alone is insufficient to open TRPV4 in OPCs in vitro. However, TRPV4 may be activated in OPCs by the synergistic effect of physiological temperature and other ligands such as arachidonic acid metabolites. The local brain temperature was recently reported to increase in response to local neuronal activity [12, 20] , which suggests that OPCs in the vicinity of highly excited neurons are exposed to higher temperatures. Thus, TRPV4 may be particularly active in OPCs located around excited neurons and contribute to neuronal activity-induced OPC proliferation and subsequent myelination. Taken together, TRPV4 stimulation may increase proliferation of OPCs in the CNS in various physiological and pathological conditions.
Many studies have reported that Ca 2+ signaling is involved in the proliferation of OPCs [7, 35] . Extracellular Ca 2+ uptake through TRPC1 is important for OPC proliferation [34] . Our results indicate that Ca 2+ signaling and PKC activation are involved in TRPV4-mediated OPC proliferation, consistent with the previous finding that PKC activation is related to OPC proliferation [4, 37] . On the other hand, TRPV4 stimulation did not affect the migration or differentiation of OPCs. However, Ca 2+ influx via voltage-dependent Ca 2+ channels has been reported to increase OPC migration and differentiation [6, 35] . The reason for this discrepancy is unknown. However, these channels have different kinetics and capacities to transport extracellular Ca 2+ into cells. They may activate distinct Ca 2+ signaling pathways via different mechanisms. Further studies are required to fully understand Ca 2+ signaling in OPCs. In conclusion, our results suggest that TRPV4 is expressed in OPCs in vivo and that TRPV4 stimulation increases OPC proliferation in vitro. Therefore, TRPV4 may involve in the regulation of the number of OPCs in the brain.
